TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05340881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bright Light Exposure
Description: Research coordinator will follow-up with participant on Days 2 \& 5, and weekly thereafter to assess for the presence of potential side effects. If side effects are present with bright light initiation and they do not resolve by Day 5, the intervention will be discontinued.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dim Light Exposure
Description: A placebo pair of glasses that is identical in form to the bright light glasses with the exception of light intensity will be used in a manner identical to the bright light glasses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Cognitive examinations will be completed in-person and remotely via an online platform; caregivers and participants will also be asked to complete questionnaires assessing fatigue, sleep, and mood. These outcomes will be completed at baseline (prior to intervention/placebo), Week 4, Week 6 (end of intervention/placebo), and Week 8 (2-weeks post intervention/placebo).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Assessment
Description: Cognitive examinations will be completed in-person and remotely via an online platform; caregivers and participants will also be asked to complete questionnaires assessing fatigue, sleep, and mood. These outcomes will be completed at baseline (prior to intervention/placebo), Week 4, Week 6 (end of intervention/placebo), and Week 8 (2-weeks post intervention/placebo).
Study: NCT04983550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride liposome injection
Description: Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin hydrochloride liposome injection
Description: Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w
Study: NCT06525493

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia
Description: The interventions are three different regional anesthesia techniques: Proximal Adductor Canal Block (ACB), iPACK (Interspace between the Popliteal Artery and the Capsule of the Posterior Knee), and Large-Volume Distal Adductor Canal Block (Large ACB distal). all three interventions were administered using ropivacaine 0.2%. However, there were differences in the volumes injected for each regional anesthesia technique. Proximal ACB: 15 mL of ropivacaine 0.2%. iPACK: 20 mL of ropivacaine 0.2%. Large ACB distal: 35 mL of ropivacaine 0.2%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia
Description: The interventions are three different regional anesthesia techniques: Proximal Adductor Canal Block (ACB), iPACK (Interspace between the Popliteal Artery and the Capsule of the Posterior Knee), and Large-Volume Distal Adductor Canal Block (Large ACB distal). all three interventions were administered using ropivacaine 0.2%. However, there were differences in the volumes injected for each regional anesthesia technique. Proximal ACB: 15 mL of ropivacaine 0.2%. iPACK: 20 mL of ropivacaine 0.2%. Large ACB distal: 35 mL of ropivacaine 0.2%
Study: NCT06490562

Intervention type: DRUG
Group type: OTHER
Intervention: PDCy
Description: Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD

Intervention type: DRUG
Group type: OTHER
Intervention: Non Cy
Description: Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
Study: NCT05196464

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy (ACT) Workshop
Description: ACT workshops are single-day workshops that last 5-6 hours. The workshops will 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from unhelpful thoughts) and strategies to willingly face experiences that cannot be changed; and 2) Committed Action Training to help Veterans clarify what matters most to them (e.g., valued domains including family, friends, spirituality, career) and what they want to stand for in life, how they want to behave, and what strengths and qualities they want to develop. Within this context, the workshop will encourage engagement in, rather than avoidance of, actions consistent with valued directions, including engagement in healthcare. Workshop participants will be given homework related to implementing a key coping skill.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: TAU will consist of a consult to a mental health provider at their rural clinic. The patient will then be scheduled for an intake and offered traditional mental health treatment options. Treatment options are likely to include outpatient individual psychotherapy, psychotherapy groups, or medication management.
Study: NCT05817448

Intervention type: DIAGNOSTIC_TEST
Intervention: HIF 1α and LC3B expression and MMP-9 level
Description: 5ml of venous blood samples will be taken from all participants at 28-40 weeks of gestation for detcetion of MMP-9 level by Enzyme-Linked Immune Sorbent Assay (ELISA) kit.~Placental tissue sample in the maternal surface will be taken during CS in placenta previa group and similar location in maternal surface will be sampled after placental delivery in control group for histopathology and immunohistochemistry for detection of HIF 1α and LC3B expression

Intervention type: DIAGNOSTIC_TEST
Intervention: HIF 1α and LC3B expression and MMP-9 level
Description: 5ml of venous blood samples will be taken from all participants at 28-40 weeks of gestation for detcetion of MMP-9 level by Enzyme-Linked Immune Sorbent Assay (ELISA) kit.~Placental tissue sample in the maternal surface will be taken during CS in placenta previa group and similar location in maternal surface will be sampled after placental delivery in control group for histopathology and immunohistochemistry for detection of HIF 1α and LC3B expression
Study: NCT04679350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
Study: NCT06646861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A combination of aerobic, resistance, balance and flexibility exercises will be included.
Study: NCT06593288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support Ventilation
Description: Conduct the Spontaneous breathing trial with pressure support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure (CPAP)
Description: Conduct the spontaneous breathing trial with CPAP
Study: NCT05741294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin 2.5 mg ointment
Description: Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.
Study: NCT04679350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline solution)
Description: Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7
Study: NCT05990270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
Study: NCT04841811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
Study: NCT04891159

Intervention type: OTHER
Intervention: Shared decision making
Description: The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
Study: NCT05154539

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Remote digital assessment
Description: Remote digital assessment of test group participants

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Remote digital assessment
Description: Remote digital assessment of test group participants

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical assessment
Description: Conventional physical assessment of control group participants
Study: NCT05497037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRF stimulation
Description: One time 500 kHZ stimulation for 15 min
Study: NCT06580314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05137444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminum hydroxide

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminum hydroxide
Study: NCT05357703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard treatment + Active B-Cure laser
Description: The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/minute.
Study: NCT05319821

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Receive ECHO training
Description: Active Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Offered ECHO training in year 5
Description: Delayed Intervention
Study: NCT05347576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393(2)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393(2)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150, D029
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150, D029
Description: QD, PO
Study: NCT05591508

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Ketogenic diet will be in the form of artificial powder which can be diluted and given through NG tube. It will be started at a ratio of 1:1 followed by daily increment (2:1,3:1 and 4:1) till a urine ketone of 2+ is seen
Study: NCT05891834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-202
Description: tablet, once daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-202
Description: tablet, once daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-202
Description: tablet, once daily, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, once daily, oral
Study: NCT04925882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector spinae plane block
Description: After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%.
Study: NCT05718375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU01-1001
Description: CU01-1001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU01-1001
Description: CU01-1001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05008276

Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

Intervention type: DRUG
Intervention: Iohexol Inj 300 MG/ML
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Study: NCT04899050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (Epidiolex)
Description: Use of Epidiolex to control absence seizures.
Study: NCT05008276

Intervention type: DRUG
Intervention: Iohexol Inj 300 MG/ML
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Intervention type: DRUG
Intervention: Dextran 40
Description: Diagnostic aid/agent used to measure glomerular size and selectivity

Intervention type: DRUG
Intervention: Dextran 40
Description: Diagnostic aid/agent used to measure glomerular size and selectivity
Study: NCT04920357

Intervention type: DRUG
Intervention: Vaccination
Description: Persons that are vaccinated within the national and regional vaccine program are invited to participate in the follow-up study.

Intervention type: DRUG
Intervention: Vaccination
Description: Persons that are vaccinated within the national and regional vaccine program are invited to participate in the follow-up study.
Study: NCT05747222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Tharapy
Description: Using a 13-inch tablet, the patient will be shown, from a third-person lateral perspective framing the palmar side of the hand, a video that repeatedly plays a simple movement of daily life (grasping a glass on the table with the hand and bringing it closer to oneself) for 5 consecutive minutes. The video should be customized based on the side being treated (ex: right hemiparesis, video framing a right hand). After 1 minute of rest, the therapist will ask the patient to perform the newly observed movement for a minimum duration of 2 minutes and a maximum of 5 minutes. The cycle will be repeated a total of 3 times, for total treatment time between 25 and 35 minutes per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc.).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc.).
Study: NCT06191627

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Patch testing
Description: Unlike many different dermatological diseases, a biopsy cannot easily distinguish ACD from irritant contact dermatitis or other forms of chronic dermatitis. Thus, the gold standard for diagnosis is patch testing. During patch testing, allergens are placed on the skin under occlusion using an aluminum disc and tape. When undergoing intensive testing for ACD, as many as 300 patches may be applied to a patient. Therefore, a large area of skin clear of rash is required, most often the back, but patches are frequently applied to the legs as well. Patches are applied by clinic patch technicians. They will proceed with their normal procedures, following the randomization to apply the patches to the appropriate location. Patches will be applied to the skin once, as is the normal standard of care. Patches are applied on day 1 and removed on day 3. Patients continue testing through day 5, though study elements will cease on day 3.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Patch testing
Description: Unlike many different dermatological diseases, a biopsy cannot easily distinguish ACD from irritant contact dermatitis or other forms of chronic dermatitis. Thus, the gold standard for diagnosis is patch testing. During patch testing, allergens are placed on the skin under occlusion using an aluminum disc and tape. When undergoing intensive testing for ACD, as many as 300 patches may be applied to a patient. Therefore, a large area of skin clear of rash is required, most often the back, but patches are frequently applied to the legs as well. Patches are applied by clinic patch technicians. They will proceed with their normal procedures, following the randomization to apply the patches to the appropriate location. Patches will be applied to the skin once, as is the normal standard of care. Patches are applied on day 1 and removed on day 3. Patients continue testing through day 5, though study elements will cease on day 3.
Study: NCT06346899

Intervention type: OTHER
Intervention: No intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No intervention
Description: This is a non-interventional study.
Study: NCT05600920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin (IL) 7-hyFc
Description: Structural Formula: NT-I7 is a fusion protein comprising human IL-7 fused to the human IgD hinge region. This in turn is fused to the N-terminal region of CH2 from IgD and two key regions of the antibody IgG4: C-terminal region of CH2 and the entire CH3 region. NT-I7 will be administered by IM injection once every 12 weeks for a total of 3 doses, with the final dose at week 24. In the absence of treatment delays due to AEs, a treatment course of 24 weeks will be pursued in all enrolled participants. The dose levels to be used in this study are 240, 480, and 720 microgram/kg. NT-I7 dosing will be determined using the weight recorded at the screening visit. The dose will be based on the participant s actual body weight, unless the participant has a BMI \>=30 kg/m2, in which case adjusted body weight will be used.
Study: NCT05092321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic Occupational Therapy
Description: Group of 4-8 children, paired with a swim buddy. Intervention techniques including discrete teaching, motor shaping, behavioral management, therapeutic relationship and individualized goals.